Most Read Articles
Rachel Soon, 2 days ago

Guidelines for local pharmacists on what actions to take during the COVID-19 pandemic have been issued by the Malaysian Pharmaceutical Society (MPS).

Elvira Manzano, 22 Nov 2017
A blood pressure (BP) reading of 130/80 mm Hg or higher is the ‘new high’ in the latest AHA/ACC* hypertension guidelines, a threshold that is tighter than the JNC 7** cutpoint of 140/90 mm Hg for stage 1 hypertension in the general population. The change will mean more patients being labelled with hypertension.
Roshini Claire Anthony, Yesterday

The reduction in bleeding events with 12-month ticagrelor monotherapy after 3-month dual antiplatelet therapy (DAPT) among high-risk patients who have undergone percutaneous coronary intervention (PCI) in the TWILIGHT* trial is consistent among patients with diabetes mellitus (DM), the TWILIGHT-DM trial showed.

02 Apr 2020
Cabozantinib plus androgen deprivation therapy (ADT) shows potent clinical activity in hormone-naïve metastatic prostate cancer (HNMPCa), according to the results of a phase II trial.

Glecaprevir with pibrentasvir effective for genotype 1 HCV

06 Dec 2019

The combination of glecaprevir and pibrentasvir (G/P) may be a viable option for patients with genotype 1 hepatitis C virus (HCV) infection who had failed prior treatment with sofosbuvir and a nonstructural protein inhibitor, a new study has shown.

The phase IIIb, open label study included four groups: cirrhotic patients given G/P for 12 (group A; n=78; median age, 62 years; 82 percent male) or 16 (group B; n=49; median age, 62 years; 82 percent male) weeks, and patients with compensated cirrhosis who received G/P with ribavirin for 12 weeks (group C; n=21; median age, 60 years; 76 percent male) or G/P alone for 16 weeks (group D; n=29; median age, 64 years; 79 percent male). The primary outcome was sustained virologic response at 12 weeks (SVR12).

Majority of the participants achieved SVR12 (91.5 percent; n=162). The corresponding rates were 90 percent, 94 percent, 86 percent and 97 percent in groups A, B, C and D, respectively.

Twelve weeks of G/P led to an SVR12 rate of 89 percent, while extending treatment to 16 weeks improved the outcome to 95 percent. Treatment failure was reported in 13 patients with HCV genotype 1a.

G/P was “well tolerated” overall, such that there were no treatment discontinuations due to adverse events (AE) or abnormal laboratory findings. Around two-thirds of the participants experienced side effects, the most common of which were fatigue, nausea and headaches. Twelve serious AEs occurred in eight patients, one of which resulted in death.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 2 days ago

Guidelines for local pharmacists on what actions to take during the COVID-19 pandemic have been issued by the Malaysian Pharmaceutical Society (MPS).

Elvira Manzano, 22 Nov 2017
A blood pressure (BP) reading of 130/80 mm Hg or higher is the ‘new high’ in the latest AHA/ACC* hypertension guidelines, a threshold that is tighter than the JNC 7** cutpoint of 140/90 mm Hg for stage 1 hypertension in the general population. The change will mean more patients being labelled with hypertension.
Roshini Claire Anthony, Yesterday

The reduction in bleeding events with 12-month ticagrelor monotherapy after 3-month dual antiplatelet therapy (DAPT) among high-risk patients who have undergone percutaneous coronary intervention (PCI) in the TWILIGHT* trial is consistent among patients with diabetes mellitus (DM), the TWILIGHT-DM trial showed.

02 Apr 2020
Cabozantinib plus androgen deprivation therapy (ADT) shows potent clinical activity in hormone-naïve metastatic prostate cancer (HNMPCa), according to the results of a phase II trial.